Altimmune Inc (ALT)
8.68
+0.28
(+3.27%)
USD |
NASDAQ |
Nov 22, 16:00
8.65
-0.03
(-0.35%)
After-Hours: 20:00
Altimmune Cash from Financing (Quarterly): 0.266M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.266M |
| June 30, 2024 | -0.046M |
| March 31, 2024 | -0.261M |
| December 31, 2023 | 72.75M |
| September 30, 2023 | 0.588M |
| June 30, 2023 | 13.06M |
| March 31, 2023 | -0.302M |
| December 31, 2022 | -0.043M |
| September 30, 2022 | 32.06M |
| June 30, 2022 | 21.58M |
| March 31, 2022 | 3.181M |
| December 31, 2021 | 12.54M |
| September 30, 2021 | 0.125M |
| June 30, 2021 | 18.02M |
| March 31, 2021 | 34.42M |
| December 31, 2020 | 22.70M |
| September 30, 2020 | 136.15M |
| June 30, 2020 | 54.54M |
| March 31, 2020 | 0.0967M |
| December 31, 2019 | 0.0449M |
| September 30, 2019 | -0.0558M |
| June 30, 2019 | -0.1561M |
| March 31, 2019 | 12.70M |
| December 31, 2018 | 31.52M |
| September 30, 2018 | 4.413M |
| Date | Value |
|---|---|
| June 30, 2018 | -3.460M |
| March 31, 2018 | 0.0185M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 12.99M |
| June 30, 2017 | -0.2008M |
| March 31, 2017 | 3.054M |
| December 31, 2016 | -0.6919M |
| September 30, 2016 | 2.060M |
| June 30, 2016 | 3.592M |
| March 31, 2016 | 0.0224M |
| December 31, 2015 | 0.0295M |
| September 30, 2015 | 0.317M |
| June 30, 2015 | 0.0422M |
| March 31, 2015 | -0.1657M |
| December 31, 2014 | 2.551M |
| September 30, 2014 | 10.50M |
| June 30, 2014 | 2.306M |
| March 31, 2014 | 1.377M |
| December 31, 2013 | 0.7917M |
| September 30, 2013 | 0.8403M |
| June 30, 2013 | 3.458M |
| March 31, 2013 | -0.0604M |
| December 31, 2012 | 0.1221M |
| September 30, 2012 | 1.208M |
| June 30, 2012 | -0.8151M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.302M
Minimum
Mar 2023
136.15M
Maximum
Sep 2020
21.07M
Average
7.858M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 211.30M |
| Viking Therapeutics Inc | 2.522M |
| Amgen Inc | -3.651B |
| Avid Bioservices Inc | 0.266M |
| NovaBay Pharmaceuticals Inc | 2.089M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.12M |
| Cash from Investing (Quarterly) | 1.199M |
| Free Cash Flow | -78.12M |
| Free Cash Flow Per Share (Quarterly) | -0.3815 |
| Free Cash Flow to Equity (Quarterly) | -27.12M |
| Free Cash Flow Yield | -13.27% |